Oxford BioMedica Achieves Full Ownership of US Subsidiary

Oxford BioMedica ( (GB:OXB) ) just unveiled an update.

Oxford BioMedica has completed the acquisition of the remaining 10% stake in its US subsidiary from Q32 Bio, Inc., achieving full ownership. This move aligns with OXB’s global strategy and strengthens its position in the viral vector manufacturing market, particularly in the US. The acquisition supports the company’s long-term growth by meeting the increasing demand for high-quality vector manufacturing, a crucial component of the expanding cell and gene therapy market. The fully integrated US facility in Bedford, MA, enhances OXB’s global network, offering lentiviral and AAV vector capabilities and supporting new programs in the US.

The most recent analyst rating on (GB:OXB) stock is a Buy with a £740.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.

Spark’s Take on GB:OXB Stock

According to Spark, TipRanks’ AI Analyst, GB:OXB is a Neutral.

Oxford BioMedica shows promising growth potential due to strong revenue increases and strategic initiatives. However, financial instability and valuation concerns weigh down the overall score.

To see Spark’s full report on GB:OXB stock, click here.

More about Oxford BioMedica

Oxford BioMedica (OXB) is a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. With 30 years of experience, OXB is a pioneer in viral vector technology, collaborating with leading pharmaceutical and biotechnology companies. The company offers expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types, supporting clients from early-stage development to commercialization. OXB is headquartered in Oxford, UK, with facilities in the UK, France, and the US.

YTD Price Performance: -23.57%

Average Trading Volume: 244,526

Technical Sentiment Signal: Sell

Current Market Cap: £340.6M

For an in-depth examination of OXB stock, go to TipRanks’ Overview page.